Aescap

About The Fund

Aescap is a venture capital firm based in Amsterdam, Netherlands, specializing in investments across the biotech spectrum. They target transformative biotech companies with a focus on sectors such as Biotech, Medical Devices (& Hospital Services), Life Science, and Oncology. Aescap operates with a comprehensive investment approach, combining a private equity mindset on the stock market with activist strategies where necessary. They predominantly invest in highly innovative publicly traded biotech and life sciences companies, supervised by an AIFM and steered by an investment team with robust experience and a successful track record. The firm's name Aescap derives from Aesculapius, the Roman god of Medicine, intertwined with 'Capital,' reflecting their dedication to the field of medical advances. Their investment philosophy is centered on selecting companies that are developing ground-breaking medicines for diseases with high unmet medical needs, thus potentially offering excellent returns without incurring substantial risks. The Aescap funds are classified as article 8 funds under the Sustainable Finance Disclosure Regulation (SFDR), combining the goal of financial gain with the promotion of a social characteristic by investing in companies that have a substantial impact on the quality of life. Their strategy hinges on backing next-generation medicine, identifying companies with outstanding management, focusing on high-growth yet undervalued companies, maintaining diversification within their strategic focus areas, and applying a disciplined buy and sell approach. The investment team, led by portfolio manager Patrick Krol, also invests significantly in the Aescap funds, aligning their interests with those of their investors. Aescap operates within a specialized market of about 1000 public biotech companies in the EU and US, leveraging their sector-specific expertise to select de-risked companies with significant earning potential. The small-sized Aescap funds aim to enable them to act flexibly and opportunistically. They have a minimum and maximum investment size of 14,960,000 euros. Aescap is committed to the continuous innovation of the life sciences sector, aiming to replace a vast majority of medicine with new treatments like RNA, gene, and cell therapies over the coming decades.